Signaling transduction pathway inhibitors target specific genetic abnormal;ities and thus are effective only in patients whose tumor characterized by these alterations. Its clear therefore that targeted drugs can be effective only in patients identified through biomarkers for personalized health care. In the era of clinical cancer genome and network biology, exciting opportunities are being developed for the next-generation biomarkers.

Related papers
1. Roukos DH, Ku CS. Clinical cancer genome and precision medicine. Ann Surg Oncol. 2012 Nov;19(12):3646-50. doi: 10.1245/s10434-012-2542-9.
2. Cho W, Ziogas DE, Katsios C, Roukos DH. Emerging personalized oncology: sequencing and systems strategies. Future Oncol. 2012 Jun;8(6):637-41.
3. Katsios C, Papaloukas C, Tzaphlidou M, Roukos DH. Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications? Expert Rev Mol Diagn. 2012 Sep;12(7):667-70. doi: 10.1586/erm.12.68.
4. Ku C, Cooper D, Iacopetta B, Roukos D. Integrating next-generation sequencing into the diagnostic testing of inherited cancer predisposition. Clin Genet. 2012 Sep 28. doi: 10.1111/cge.12028.
5. Roukos DH. Dynamics of genome 'iPOP': predicting disease or 'narciss-ome'? Expert Rev Mol Diagn. 2012 Jul;12(6):545-8.

Scientific and clinical evidence suggest major limitations of currently used targeted drugs in cancer treatment. Even among a few signaling transduction inhibitors demonstrating tumor responsiveness reflected by clinical manifestation of prolonged overall survival, this effect is temporary for a majority of patients.
To overcome this resistance, novel drugs are proposed targeting structutal and functional molecular and signaling networks changes characterizing cancer cells.

Related papers
1.  Roukos DH, Ziogas DE, Papaloukas C, Baltogiannis G. Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. Future Oncol. 2012 Nov;8(11):1373-6. doi: 10.2217/fon.12.140. 
2.  Roukos DH. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Expert Rev Proteomics. 2012 Aug;9(4):349-53. doi: 10.1586/epr.12.37.
3. Current Drug Discovery and Development with an Eye Towards the Future. Kapetanovic ?? , Division of Cancer Prevention, National Cancer Institute, Bethesda, MD USA. 2012
4.  Camacho DF, Pienta KJ. Disrupting the networks of cancer. Clin. Cancer Res. 2012; 18(10): 2801- 2808 .